Islet transplantation has recently emerged as one of the most promising therapeutic approaches to improving glycometabolic control in diabetic patients. The Edmonton trials demonstrated a marked improvement in the sho...Islet transplantation has recently emerged as one of the most promising therapeutic approaches to improving glycometabolic control in diabetic patients. The Edmonton trials demonstrated a marked improvement in the short-term rate of success of islet transplantation, with an 80% rate of insulin-independence being at 1 year after transplantation, as reported by several institutions worldwide. Unfortunately, this rate consistently decreases to 10% by 5 years post-transplantation.展开更多
采用 ELISA法对 87例肾移植患者在术前及术后都测定 s CD30。分析 s CD30在肾移植患者中对排斥反应的预测及诊断意义。结果表明 s CD30术前、术后均为阳性的患者 ,术后发生急性排斥反应的为 35 .7% ,高致敏组人群检测结果阳性率较高。...采用 ELISA法对 87例肾移植患者在术前及术后都测定 s CD30。分析 s CD30在肾移植患者中对排斥反应的预测及诊断意义。结果表明 s CD30术前、术后均为阳性的患者 ,术后发生急性排斥反应的为 35 .7% ,高致敏组人群检测结果阳性率较高。移植前评估血清s CD30 ,为临床考虑随后的肾移植排斥反应危险性提供了相关信息。展开更多
基金This work was supported by a grant from the National Basic Research Program of China （No. 2009CB522401）, Key Program of the Natural Science Foundation of China （No. 30930088）, and the Program of Natural Science Foundation of China （No. 30872382）.
文摘Islet transplantation has recently emerged as one of the most promising therapeutic approaches to improving glycometabolic control in diabetic patients. The Edmonton trials demonstrated a marked improvement in the short-term rate of success of islet transplantation, with an 80% rate of insulin-independence being at 1 year after transplantation, as reported by several institutions worldwide. Unfortunately, this rate consistently decreases to 10% by 5 years post-transplantation.
文摘采用 ELISA法对 87例肾移植患者在术前及术后都测定 s CD30。分析 s CD30在肾移植患者中对排斥反应的预测及诊断意义。结果表明 s CD30术前、术后均为阳性的患者 ,术后发生急性排斥反应的为 35 .7% ,高致敏组人群检测结果阳性率较高。移植前评估血清s CD30 ,为临床考虑随后的肾移植排斥反应危险性提供了相关信息。
